Registered forecast

25% registered probability event by 2027-03-10 Unresolved

NICE publishes technology appraisal guidance on Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608] on or before 2027-03-10

FF-067 Registered Unresolved
registered due
Our estimate
25%
an estimate, not a reading
Action by
2027-03-10
known at this date
Reading window
2026-11-11 → 2027-03-10
known at this date
Decision stage
  1. 5 Guideline
  2. 6 Regulatory
  3. 7 Coverage
Baselines it has to beat
  • Authority base rate 50%
  • Calendar cycle 50%
  • Analyst proxy 25%
  • Known at this date
  • The registered estimate, uncertain
  • Not yet knowable at this date

At this date the record was registered at 25% and the deadline had not been reached. The outcome was not yet knowable.

The outcome is not yet knowable at this date.

nextconsensus.com/forecast/ff-067/ registry snapshot 2026-11-21 Share image

NextConsensus registered this probability on 2026-11-10. It is one of 28 registered NICE scheduled-date forecasts.

The proposition

What was registered

NICE publishes final technology appraisal guidance for the appraisal 'Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B' [ID6608], with a publication date on or before 2027-03-10, the expected publication date shown on its in-development page (https://www.nice.org.uk/guidance/indevelopment/gid-ta11803) on 2026-11-10.
Who decides
National Institute for Health and Care Excellence (NICE), Technology Appraisal Committee C (England)
Who has to act
Rung 7: Payer/coverage action — NCD, LCD, formulary change, step-therapy revision, or access expansion/restriction by CMS, MACs, or major commercial payers.
Counted with
NICE guidance by scheduled date
Scope
Chronic hepatitis B

The estimate

Our estimate and what it has to beat

25% our estimate, method v0.1.0 · frozen at the 2026-11-10 cutoff

The estimate that the named body takes the action by the deadline, from what was public at the cutoff.

The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.

Authority base rate 50%

ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. The share of NICE technology appraisals published on or before the expected date shown at the cutoff is not yet counted; the calendar's census will count it. Expected dates are revised often, most when a committee meeting does not reach a final recommendation, a marketing authorisation is late, or a company asks for time.

Calendar cycle 50%

A clock-only model: one committee meeting on 12 January 2027, 57 days before the expected date, is treated as on schedule: the model assumes final draft guidance and an appeal period fit in that time, and knows nothing about the evidence or the authorisation.

Analyst proxy 25%

An analyst reading the project page and scope on 2026-11-10 would weigh a first-of-class product for an unmet goal (functional cure) and a schedule NICE set, against a single meeting with no slack for consultation, no UK marketing authorisation at scope, and a cost-effectiveness case against generic comparators. Estimated by reconstructing that read, not by surveying analysts.

Technology appraisal (NICE): offered on judgment, with no calibration figure until 15 in the class have resolved.

The method and every record are public, so you can check the work.

The clock

Dates that constrain the record

Evidence as of
2026-11-10
Nothing after this date informed the estimate. known at this date
Registered
2026-11-10
Frozen and hashed. known at this date
Reading window
2026-11-11 → 2027-03-10
When the outcome can be read against the rule. known at this date
Event by
2027-03-10
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar known at this date
ledger 87c0dd2271bc8d474cacdf39a6d8b5f53cbef5744ebd19afa7a327271e4da3bd
· operator record jc-1794354012004-84459d77

Around this record

Confidential Asset & Milestone Evaluation

Evaluating an asset or milestone that NICE could move?

Name the asset, the deciding authority, and the date your team prepares for: a P&T review, an HTA submission, a label negotiation, a deal closing, or a milestone dispute. It can be an asset you sponsor, evaluate, finance, advise on, or rely on. Every commercial evaluation applies the same pre-registration standard and primary-source verification as this record, delivered privately under mutual NDA.

$9,500 · 10 business days One milestone, authority, and target date: the dated evidence baseline, authority divergence redline, evidence stall assessment, and transition probability. Delivered within ten business days of the kickoff call, or you don't pay.
Under mutual NDA Held to the same standard as this public record: who decides, the resolution rule, and the baselines.
Reconstructing a record? For an earnout, milestone dispute, or expert report: the $5,000 Historical Evidence-State Dossier, one proposition at one cutoff, 5 business days, no probabilities. For an asset's whole history across the class: the $35,000 Regulatory & Coverage Diligence Dossier, 15 business days.

Resolution

How we’ll check the result

Resolves YES if the NICE technology appraisal guidance page published from project ID6608 shows a publication date ('Published: <date>') on or before 2027-03-10, whatever the guidance recommends. The adjudicator finds the page from the in-development page above, which links to or redirects to the published guidance, or by searching nice.org.uk for ID6608. Resolves NO if the guidance is published after 2027-03-10, if the expected date is revised and nothing is published by 2027-03-10, if the appraisal is paused or suspended past that date, or if it is terminated. A terminated appraisal stays in the denominator and resolves NO, as the calendar's rule for this class says. Resolves cancelled_external only if NICE removes the appraisal from its work programme without publishing anything. The frozen date is the one archived at the cutoff; a later revision does not move it. Read no earlier than 2027-03-17. The recommendation itself is a different question and is not scored here. Resolves VOID, with the reason recorded, only if NICE stops publishing technology appraisal guidance pages with publication dates, so that no publication date for this appraisal can be read from nice.org.uk or its successor; while a publication date can be read, the rule stands.
The rule as registered
Resolves YES if the NICE technology appraisal guidance page published from project ID6608 shows a publication date ('Published: <date>') on or before 2027-03-10, whatever the guidance recommends. The adjudicator finds the page from the in-development page above, which links to or redirects to the published guidance, or by searching nice.org.uk for ID6608. Resolves NO if the guidance is published after 2027-03-10, if the expected date is revised and nothing is published by 2027-03-10, if the appraisal is paused or suspended past that date, or if it is terminated. A terminated appraisal stays in the denominator and resolves NO, as registry/CALENDAR.md's rule for this class says. Resolves cancelled_external only if NICE removes the appraisal from its work programme without publishing anything. The frozen date is the one archived at the cutoff; a later revision does not move it. Read no earlier than 2027-03-17. The recommendation itself is a different question and is not scored here. Resolves VOID, with the reason recorded, only if NICE stops publishing technology appraisal guidance pages with publication dates, so that no publication date for this appraisal can be read from nice.org.uk or its successor; while a publication date can be read, the rule stands.

Source the rule names: https://www.nice.org.uk/guidance/indevelopment/gid-ta11803, https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance

After the deadline, the founder (Kanav Jain) reads the outcome against the frozen public source; unratified automated readings are labelled machine-resolved and excluded from class calibration figures.

What this record will show once it resolves

Beside every result, the count for its class (NICE guidance by scheduled date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.

The finding
As the rule above reads it: occurred on time, did not occur, or left unscored.
The readers and their sources
After the deadline, the founder (Kanav Jain) reads the frozen public source named above under the registered rule (or automated checks record a machine-resolved reading). Who adjudicated it and the source read are published here so any reader can verify the outcome. Adjudication applies the frozen rule to the named public source so any reader can verify the reading independently.
The number against its baselines
25% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.

Email me when FF-067 resolves

One email when the result is published, then nothing; the address is deleted a month later.

Reasoning

What the number rests on

The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record, are held in the ledger, and are covered by its hash.

The state of the record at the cutoff

Recorded as they stood on 2026-11-10.

review pathway
STA Standard by Technology Appraisal Committee C (enquiries to TACommC) (SRC-001)
submission type
New appraisal; company GlaxoSmithKline (SRC-001). No UK marketing authorisation at the June 2026 final scope (SRC-003).
evidence class
not applicable — the proposition is a publication date, not an evidence judgement
pivotal n
not applicable
endpoint type
not applicable — the proposition is a publication date
approved competitors in class
Comparators in the final scope: tenofovir disoproxil, entecavir, peginterferon alfa-2a, tenofovir alafenamide and no treatment; NICE TA96, TA153 and TA173 recommend peginterferon alfa-2a, entecavir and tenofovir disoproxil (SRC-003).
months since last guideline revision
not applicable
panel cycle position
Committee meeting 1 scheduled 12 January 2027, 57 days before the expected publication date of 10 March 2027; no earlier meeting (SRC-001). The committees page lists Committee C meetings only to 01 December 2026 (SRC-004).
sponsor request status
No company request for more time or pause is recorded on the project page (SRC-001).
odac referral
not applicable — NICE committee, not an FDA advisory committee
sponsor state change
none recorded in the archived sources

Sources

Everything the estimate was built from

Each was retrieved on or before the 2026-11-10 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.

  1. SRC-001 NICE in-development page (Project information tab) for GID-TA11803. Shows 'Expected publication date: 10 March 2027', status 'In progress', 'Process: STA Standard', provisional schedule (committee meeting 1: 12 January 2027; expected publication 10 March 2027), company GlaxoSmithKline (bepirovirsen), enquiries to TACommC, External Assessment Group SHTAC, and the timeline (topic selected 16 June 2025; scope consultation 06 March - 07 April 2026; invitation to participate 08 June 2026).

    https://www.nice.org.uk/guidance/indevelopment/gid-ta11803

    Retrieved 2026-11-10 · sha256 a3a811d1ca1674510572178594a1fd5034a4c2d8b94cbbaaa2da64c7acff5bed

  2. SRC-002 NICE Project documents tab for GID-TA11803. Lists the final scope, final stakeholder list, response to scope comments and scoping equality impact assessment (published 08 June 2026) and the draft scope post referral (06 March 2026); no committee papers, no draft guidance, no final draft guidance and no final guidance listed.

    https://www.nice.org.uk/guidance/indevelopment/gid-ta11803/documents

    Retrieved 2026-11-10 · sha256 e51464618ac80b0a42abaeb133d8c67fe09f5bebd9aaa95ce251b7fb80951c3e

  3. SRC-003 NICE final scope for ID6608 (issue date June 2026). 'Bepirovirsen (brand name unknown, GSK) does not currently have a marketing authorisation in the UK for treating chronic hepatitis B'; studied against placebo in people on a stable treatment regimen; comparators include tenofovir disoproxil, entecavir, peginterferon alfa-2a, tenofovir alafenamide and no treatment; 'Guidance will only be issued in accordance with the marketing authorisation.'

    https://www.nice.org.uk/guidance/gid-ta11803/documents/final-scope

    Retrieved 2026-11-10 · sha256 b1d27f386a0d15643a43d1e487121cf0fabc80b5161f56386a0d66107e4a6490

  4. SRC-004 NICE Technology appraisal committees page, retrieved 2026-11-10. Lists next meeting dates for Committees A to D through December 2026, including Committee C on 03 November and 01 December 2026; no 2027 date is listed.

    https://www.nice.org.uk/get-involved/our-committees/nice-committee-meetings/technology-appraisal-committees

    Retrieved 2026-11-10 · sha256 5f7e953ea377383b9a7e6119345c399f25f0458952a201d5383b23599b088491